Rebuilding Maternal Safety Tools for Modern Childbirth

Raydiant Oximetry

Rebuilding Maternal Safety Infrastructure for Modern Childbirth

Childbirth remains one of the most dangerous and under-innovated moments in healthcare.

Despite billions spent annually on hospital obstetrics, maternal mortality in the United States continues to rise, emergency C-section rates have increased more than 500% over the past several decades, and yet newborn injury rates have shown little meaningful improvement. At the same time, postpartum hemorrhage (severe bleeding after childbirth) remains one of the leading causes of maternal death globally — even though the majority of these deaths are considered preventable.

The core issue is not a lack of medical intervention. It is a lack of accurate information.

Today’s standard fetal monitoring systems primarily track fetal heart rate, but they do not directly measure whether a baby is actually receiving enough oxygen during labor. This creates a dangerous clinical gap. In practice, hospitals are often forced to make high-stakes decisions based on incomplete or unreliable signals. The result is a system that can both overreact and underreact at the same time: unnecessary emergency C-sections are performed, while truly distressed babies can still go undetected. Raydiant Oximetry was founded to solve this problem.

Based in California, Raydiant Oximetry is developing a suite of maternal-fetal monitoring technologies designed to improve outcomes for both mothers and babies during childbirth. Its flagship product, Lumerah™, is the world’s first non-invasive fetal pulse oximeter — a device designed to directly measure fetal oxygen levels during labor.

The concept is simple but transformative: if physicians can more accurately determine whether a fetus is actually in distress, they can make better decisions about when intervention is truly necessary. That has implications not only for safety and outcomes, but also for healthcare costs, surgical utilization, and long-term neonatal complications.

Raydiant’s technology is designed to integrate into existing hospital labor and delivery workflows rather than requiring hospitals to rebuild infrastructure from scratch. This matters. In healthcare, adoption is often determined less by whether a technology works and more by whether clinicians can realistically use it inside already strained systems.

Early clinical data has been promising. According to company materials, Lumerah demonstrated significantly higher specificity than conventional fetal heart rate monitoring systems, meaning it may substantially reduce false alarms that can lead to unnecessary emergency C-sections. The company also reported improved sensitivity, which could help clinicians identify babies experiencing true oxygen deprivation earlier and more accurately.

Importantly, Raydiant is not approaching maternal health as a niche market or purely mission-driven category. The company is targeting some of the largest and most economically burdensome problems in obstetrics. Emergency C-sections, birth injuries, neonatal intensive care utilization, and postpartum hemorrhage collectively represent billions in annual healthcare spending and downstream costs. This is precisely the type of “hiding in plain sight” healthcare problem that historically becomes obvious only after innovation changes the standard of care.

Raydiant’s second product, Daisy™, is designed to address postpartum hemorrhage in women undergoing cesarean deliveries. Current hemorrhage treatment devices are often limited by when and how they can be used during labor. Daisy is intended to proactively prevent hemorrhage by mechanically restoring uterine tone and helping physicians monitor blood loss earlier in the process.

The broader market opportunity is substantial. The global fetal monitoring market alone is measured in the billions, while postpartum hemorrhage devices represent another rapidly growing category. Yet beyond market size, Raydiant reflects a larger structural shift now occurring in healthcare and venture capital alike: women’s health is increasingly being recognized not as a specialty category, but as one of the largest underdeveloped sectors in modern medicine.

That shift is beginning to attract major strategic attention. Raydiant has received support from organizations including the Gates Foundation and March of Dimes and has announced a strategic partnership with GE HealthCare, one of the global leaders in fetal monitoring technology.

What makes Raydiant particularly compelling is that the company is not simply building another medical device. It is attempting to modernize the decision-making infrastructure surrounding childbirth itself.

For decades, maternal healthcare has suffered from a dangerous normalization of poor outcomes. Raydiant’s thesis challenges that assumption directly: better data leads to better decisions, and better decisions can save lives.

In a healthcare system increasingly forced to balance quality outcomes, rising costs, workforce shortages, and health equity gaps simultaneously, technologies that improve both clinical accuracy and operational efficiency are likely to become increasingly valuable.

Maternal health has long been treated as an overlooked corner of healthcare innovation. Companies like Raydiant suggest that era may finally be ending.